- In July 2024, Sun Pharmaceutical Industries Limited announced that the U.S. Food and Drug Administration (FDA) had approved LEQSELVI (deuruxolitinib) 8 mg tablets for the treatment of adults with severe alopecia areata. LEQSELVI, a JAK inhibitor, targets the root cause of alopecia areata and has been clinically proven to provide statistically significant efficacy
- In June 2024, it was published in The Harvard Gazette that Researchers from Brigham and Women’s Hospital and MIT have developed a microneedle patch that painlessly targets areas affected by alopecia areata. This novel approach aims to modulate the immune response locally, potentially reversing hair loss without systemic side effects
- In June 2024, Equillium Inc. announced positive topline results from its Phase 2, single-dose, proof-of-concept (PoC) study of EQ101 in adult patients with moderate to very-severe alopecia areata (AA), an autoimmune condition where immune cells attack hair follicles, leading to hair loss
- In June 2023, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had granted approval for LITFULO (ritlecitinib), a once-daily oral treatment for individuals aged 12 and older with severe alopecia areata. The recommended dosage for LITFULO is 50 mg. This marks it as the first and only FDA-approved treatment for adolescents (12+) suffering from severe alopecia areata
- In June 2022, Eli Lilly and Company and Incyte announced that the U.S. Food and Drug Administration (FDA) had approved OLUMIANT (baricitinib), a once-daily oral treatment, as the first systemic therapy for adults with severe alopecia areata (AA). The medication is available in 4-mg, 2-mg, and 1-mg tablets, with a recommended starting dose of 2 mg per day, which can be increased to 4 mg per day if the treatment response is insufficient
